This tag is associated with 11 posts

The dark side of Obamacare: The unintentional outcomes

Obamacare may reduce labour force participation The Congressional Budget Office (CBO)’s latest Budget and Economic Outlook forecast has come under significant scrutiny in the media since its release, mainly due to political and social controversy surrounding the Affordable Care Act (ACA) and the far-reaching impact the new healthcare reform law will have on the US … Continue reading

Pharma’s key drivers for 2014

In many ways, 2014 has kicked off in a very similar way to how 2013 started for the global pharmaceutical industry: with a major setback. In 2013, this came at the hands of the unexpected FDA non-approval of Novo Nordisk’s new diabetes treatment Tresiba (insulin degludec) in the United States. In 2014, the bad news … Continue reading

The US: Update on the economy and healthcare

As we begin the new year, let’s take some time to look at what we expect to happen on the economic front — for the US in general and then in healthcare more specifically. An overview of the US economy On the economy front, the US appears to bounce back. The real GDP growth in … Continue reading

Is the US fully prepared for major changes under Obamacare in 2014?

The US healthcare system is going through one of the biggest overhauls in its history. Provisions mandating healthcare insurance to all Americans under President Obama’s flagship initiative comes into effect. And while the Affordable Care Act (ACA) promises expanded and affordable healthcare coverage to approximately 15% of the population that has long gone uninsured, concerns … Continue reading

Could the US government shutdown undermine healthcare reform in the US?

On 1 October, health insurance marketplaces were officially launched in the US, offering affordable health care coverage to millions of uninsured Americans for the first time – a key milestone for the United States. And while the higher than expected visits to the online marketplaces led to some technical issues, attention was directed away from … Continue reading

Biosimilars in the US: The battle for hearts and minds heats up as states stake their claims in biosimilars substitution legislation

The dust has hardly settled following debates over the creation of health insurance exchanges – under the provisions of the Affordable Care Act (ACA; often referred to as ‘Obamacare’) in the United States – and there is a new battle under way. This one has attracted less attention in the media that the controversial insurance … Continue reading

340B: The debate over the US drug discount programme picks up speed

Since I last wrote about the 340B debate in the US, the controversy over this outpatient drug discount programme – originally designed to address uncompensated care costs for providers serving a significant number of uninsured and low-income patients – has gone full swing. Just last month, a number of prominent industry trade groups and other … Continue reading

Make or Break for US Health Reform as Presidential Elections Loom

On 6 November, Americans will be voting for President, for all seats in the House of Representatives, and a third of seats in the Senate. But aside from that, they will also be voting on the future healthcare system of the United States. It is a rare thing for elections to provide such a stark … Continue reading

The Mounting Controversy over Oncology Drug Prices in the US: “340B” Comes Under the Spotlight

Against the general backdrop of debate in the countdown to the US presidential election, another, slightly more obscure debate has been intensifying which concerns one aspect of that country’s healthcare system – namely, the 340B drug pricing programme. Read on to see why this programme has come under the spotlight and why it sits at … Continue reading

More Americans to Face ObamaCare Financial Penalties

As the battle for hearts and minds in the run-up to US presidential elections heats up, a newly published report by the US Congressional Budget Office (CBO) has given critics cause to attack the healthcare bill and its chief proponent President Barrack Obama. ObamaCare, as the “Affordable Care Act” (ACA) is often referred to, requires … Continue reading

Enter your email address to follow this blog and receive notifications of new posts by email.

Download extract from IHS Flexible Pricing strategies multi client study
Drug Price Erosion Multi Client Study extract download

About This Blog

In this blog, our experts share regular insights on the global life sciences industry. Join us as we look at issues in healthcare policy, market access, pricing and reimbursement and R&D. Comments are welcome!
40 countries covered. Download a sample chapter on Brazil
Download a complimentary white paper on market-access risk ratings
Download a sample of the primary research and analysis on French P&R reform

Follow IHS Life Sciences on Twitter


Get every new post delivered to your Inbox.

Join 332 other followers